FDA’s List Of Potential Rx Safety Signals Is 30 Percent Name/Packaging Related
This article was originally published in The Pink Sheet Daily
Agency Web site that lists initial investigations based on AERS data fulfills FDAAA mandate.
You may also be interested in...
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
Despite receiving a “complete response” letter and manufacturing warning letter on the same day, Genzyme remains upbeat about the likelihood of approval for its 2,000L scale-up of Myozyme.
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm